story of the week
Safety and Tolerability of CP101 for the Prevention of Recurrent Clostridioides difficile Infection
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Gastroenterology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Safety and Tolerability of CP101, a full spectrum, oral microbiome therapeutic for the prevention of recurrent C. difficile infection: A Phase 2 Randomized Controlled Trial
Gastroenterology 2024 Oct 02;[EPub Ahead of Print], JR Allegretti, CR Kelly, T Louie, M Fischer, S Hota, B Misra, NW Van Hise, E Yen, JS Bullock, M Silverman, I Davis, SK McGill, DS Pardi, R Orenstein, A Grinspan, N El-Nachef, P Feuerstadt, TJ Borody, S Khanna S, S Budree, Z KassamFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.